Brian Guan-Chyun Liu bought $50.0M of CG Oncology (CGON)
Executed Sep 11 2025, disclosed Sep 15 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 15 2025), the stock returned +22.4% (delay-adjusted); from the execution session (Sep 11 2025), +33.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Brian Guan-Chyun Liu (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in CG Oncology, Inc. (CGON). Across 1 priced purchase filing, the average 21-session return was +8.0% from execution and +3.3% from disclosure (delay-adjusted; derived). The largest single filing was $24.8M of CGON (371,085 sh × $66.87, as filed), executed Jun 25.
Healthcare · CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→371,085 sh × $66.87
Exec Jun 25
Filed Jun 29 · 5:26 PM ET